11.01.02
Indication: Osteoarthritis
Source: Archives of Internal Medicine, 2002;162:2113-2123
Research: Approximately 200 patients with knee osteoarthritis randomly received either 1500 mg of oral glucosamine sulphate daily or a placebo over a period of three years. To determine the progression of knee osteoarthritis, researchers measured changes in radiographic minimum joint space width in the medial compartment of the tibiofemoral joint, and assessed symptoms using the algo-functional indexes of Lequesne and WOMAC (Western Ontario and McMaster Universities).
Results: Researchers reported that the osteoarthritis in study participants was of mild to moderate severity at enrollment, with average joint space widths of slightly less than 4 mm and a Lequesne index score of less than nine points. With placebo use, there was progressive joint space narrowing after three years, of an average -.19 mm. Conversely, there was no average change with glucosamine sulphate use. Furthermore fewer patients treated with glucosamine sulphate experienced predefined severe narrowings. Disease symptoms improved modestly with placebo use but as much as 20-25% with glucosamine sulphate use, they found, with significant final differences on the Lequesne index and the WOMAC total index and pain, function and stiffness subscales.
Source: Archives of Internal Medicine, 2002;162:2113-2123
Research: Approximately 200 patients with knee osteoarthritis randomly received either 1500 mg of oral glucosamine sulphate daily or a placebo over a period of three years. To determine the progression of knee osteoarthritis, researchers measured changes in radiographic minimum joint space width in the medial compartment of the tibiofemoral joint, and assessed symptoms using the algo-functional indexes of Lequesne and WOMAC (Western Ontario and McMaster Universities).
Results: Researchers reported that the osteoarthritis in study participants was of mild to moderate severity at enrollment, with average joint space widths of slightly less than 4 mm and a Lequesne index score of less than nine points. With placebo use, there was progressive joint space narrowing after three years, of an average -.19 mm. Conversely, there was no average change with glucosamine sulphate use. Furthermore fewer patients treated with glucosamine sulphate experienced predefined severe narrowings. Disease symptoms improved modestly with placebo use but as much as 20-25% with glucosamine sulphate use, they found, with significant final differences on the Lequesne index and the WOMAC total index and pain, function and stiffness subscales.